Schall Law Firm Targets Soleno and Ultragenyx in Dual Securities Fraud Actions

The simultaneous announcement of securities fraud lawsuits against Soleno Therapeutics (SLNO) and Ultragenyx Pharmaceutical (RARE) by the Schall Law Firm underscores a period of heightened legal scrutiny for the biotechnology sector. These filings, both announced on March 12, 2026, target companies that operate in the high-risk, high-reward arena of rare disease and orphan drug development. In the life sciences industry, where valuations are often tethered to clinical trial milestones and regulatory feedback, any perceived lack of transparency can lead to swift and aggressive litigation from shareholder rights firms. These cases typically hinge on the 'fraud-on-the-market' theory, alleging that the companies made materially false or misleading statements that artificially inflated stock prices before a corrective disclosure caused significant investor losses.

For Soleno Therapeutics, the litigation arrives at a critical juncture in its corporate lifecycle. As a company focused on Prader-Willi syndrome (PWS), its market performance is heavily dependent on the clinical success of its lead candidate, Diazoxide Choline Controlled-Release (DCCR). While the specific triggers for the Schall Law Firm’s action often involve undisclosed FDA communications or nuanced interpretations of trial data, the broader implication is a challenge to the company's disclosure integrity. In the RegTech space, this highlights the growing need for robust compliance systems that can audit internal communications against public statements in real-time to prevent the 'disclosure gaps' that plaintiff firms exploit.

“

The simultaneous announcement of securities fraud lawsuits against Soleno Therapeutics (SLNO) and Ultragenyx Pharmaceutical (RARE) by the Schall Law Firm underscores a period of heightened legal scrutiny for the biotechnology sector.

Ultragenyx Pharmaceutical faces a similar challenge, though its broader pipeline of gene therapies and metabolic treatments provides a different risk profile. The Schall Law Firm’s move to consolidate investor interest in a lead plaintiff role suggests a significant class of affected shareholders. In securities litigation, the lead plaintiff appointment is a pivotal procedural step; the individual or institution selected by the court will have the authority to choose lead counsel and negotiate potential settlements. For Ultragenyx, this legal overhang could complicate future capital raises or strategic partnerships, as potential collaborators often conduct deep due diligence on pending litigation that alleges systemic misrepresentation.